Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S21, June 2016

Combination BM-MSC with BM-MNC is Better Than BM-MNC Alone in Resolution of Large Ischemic Ulcers: A Phase II/III Clinical Randomised Study

      Background: We previously demonstrated that combination bone marrow derived cultured mesenchymal stromal cell (BM-MSC) with bone marrow derived unselected mononuclear cell (BM-MNC) may help induce angiogenesis in diabetic patients with critical limb ischemia. In this new randomized Phase II/III clinical trial, we compared autologous BM-MSC with BM-MNC (Group A) versus BM-MNC alone (Group B) in severe lower limb ulcers secondary to critical limb ischemia with the aim of avoiding amputations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect